Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1887 1
1892 1
1928 1
1932 1
1934 1
1946 5
1954 2
1955 4
1958 1
1968 1
1970 3
1984 1
1986 1
1991 1
1992 3
1994 2
1997 2
1998 5
1999 6
2001 2
2002 6
2003 3
2004 1
2005 10
2006 7
2007 11
2008 10
2009 12
2010 9
2011 6
2012 6
2013 8
2014 11
2015 18
2016 17
2017 19
2018 9
2019 20
2020 23
2021 20
2022 19
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: basu k. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Among authors: basu k. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1.
Morita M, Prudent J, Basu K, Goyon V, Katsumura S, Hulea L, Pearl D, Siddiqui N, Strack S, McGuirk S, St-Pierre J, Larsson O, Topisirovic I, Vali H, McBride HM, Bergeron JJ, Sonenberg N. Morita M, et al. Among authors: basu k. Mol Cell. 2017 Sep 21;67(6):922-935.e5. doi: 10.1016/j.molcel.2017.08.013. Epub 2017 Sep 14. Mol Cell. 2017. PMID: 28918902 Free article.
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. Khanani AM, et al. Among authors: basu k. JAMA Ophthalmol. 2020 Sep 1;138(9):964-972. doi: 10.1001/jamaophthalmol.2020.2699. JAMA Ophthalmol. 2020. PMID: 32729897 Free PMC article. Clinical Trial.
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, Chang A, Csaky KG, Haskova Z, Lin H, Ruiz CQ, Ruamviboonsuk P, Silverman D, Wykoff CC, Willis JR. Eter N, et al. Among authors: basu k. Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar. Ophthalmol Sci. 2021. PMID: 36246184 Free PMC article.
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C. Khanani AM, et al. Among authors: basu k. Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec. Ophthalmol Sci. 2021. PMID: 36246941 Free PMC article.
Viroporins of Mpox Virus.
Basu K, Krugliak M, Arkin IT. Basu K, et al. Int J Mol Sci. 2023 Sep 7;24(18):13828. doi: 10.3390/ijms241813828. Int J Mol Sci. 2023. PMID: 37762131 Free PMC article.
Modeling repetitive, non-globular proteins.
Basu K, Campbell RL, Guo S, Sun T, Davies PL. Basu K, et al. Protein Sci. 2016 May;25(5):946-58. doi: 10.1002/pro.2907. Epub 2016 Mar 16. Protein Sci. 2016. PMID: 26914323 Free PMC article. Review.
Triads in Ophthalmology: A Comprehensive Review.
Tripathy K, Sharma YR, Chawla R, Basu K, Vohra R, Venkatesh P. Tripathy K, et al. Among authors: basu k. Semin Ophthalmol. 2017;32(2):237-250. doi: 10.3109/08820538.2015.1045150. Epub 2015 Jul 6. Semin Ophthalmol. 2017. PMID: 26148300 Review.
280 results